Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relative effectiveness of the second booster COVID-19 vaccines against laboratory confirmed SARS-CoV-2 infection in healthcare workers: VEBIS HCW VE cohort study (1 October 2022-2 May 2023).
Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Zvirbulis V, Zavadska D, Szułdrzyński K, Gaio V, Popescu CP, Craiu M, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Krievins D, Barzdina EA, Melo A, Kosa AG, Miron VD, Muñoz-Almagro C, Milagro AM, Bacci S, Kramarz P, Nardone A; VEBIS HCW Study Group. Savulescu C, et al. Among authors: bacci s. Vaccine. 2024 Dec 25;45:126615. doi: 10.1016/j.vaccine.2024.126615. Online ahead of print. Vaccine. 2024. PMID: 39724693
Photodynamic Therapy 2.0.
Kang K, Bacci S. Kang K, et al. Among authors: bacci s. Biomedicines. 2024 Oct 22;12(11):2425. doi: 10.3390/biomedicines12112425. Biomedicines. 2024. PMID: 39594992 Free PMC article.
Incidence of SARS-CoV-2 Infection Among European Healthcare Workers and Effectiveness of the First Booster COVID-19 Vaccine, VEBIS HCW Observational Cohort Study, May 2021-May 2023.
Savulescu C, Prats-Uribe A, Brolin K, Lovrić Makarić Z, Uusküla A, Panagiotakopoulos G, Bergin C, Fleming C, Agodi A, Bonfanti P, Murri R, Zvirbulis V, Zavadska D, Szuldrzynski K, Machado A, Popescu CP, Craiu M, Cisneros M, Latorre-Millán M, Petrović G, Lohur L, Tryfinopoulou K, McGrath J, Ferguson L, Barchitta M, Spolti A, de Gaetano Donati K, Abolina I, Gravele D, Gaio V, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sarajlić G, Amerali M, Sui J, Kenny C, Rapisarda V, Rossi M, Lamonica S, Krievins D, Barzdina EA, Palmira Amaral A, Kosa AG, Miron VD, Muñoz-Almagro C, Milagro AM, Bacci S, Kramarz P, Nardone A, The Vebis Hcw Ve Study Group. Savulescu C, et al. Among authors: bacci s. Vaccines (Basel). 2024 Nov 19;12(11):1295. doi: 10.3390/vaccines12111295. Vaccines (Basel). 2024. PMID: 39591197 Free PMC article.
Monovalent XBB.1.5 COVID-19 vaccine effectiveness against hospitalisations and deaths during the Omicron BA.2.86/JN.1 period among older adults in seven European countries: A VEBIS-EHR network study.
Nunes B, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, Moustsen-Helms IR, Sacco C, Fabiani M, Castilla J, Martínez-Baz I, Meijerink H, Machado A, Soares P, Ljung R, Pihlström N, Nardone A, Bacci S, Monge S; VEBIS-EHR working group. Nunes B, et al. Among authors: bacci s. Expert Rev Vaccines. 2024 Jan-Dec;23(1):1085-1090. doi: 10.1080/14760584.2024.2428800. Epub 2024 Nov 25. Expert Rev Vaccines. 2024. PMID: 39535047 Free article.
Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS-CoV-2 Infection in Older Adults During the JN.1 Lineage-Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023-1 March 2024.
Merdrignac L, Laniece Delaunay C, Verdasca N, Vega-Piris L, O'Donnell J, Sève N, Trobajo-Sanmartín C, Buda S, Hooiveld M, Rodrigues AP, Túri G, Latorre-Margalef N, Mlinarić I, Lazar M, Maurel M, Castrillejo D, Bennett C, Rameix-Welti MA, Martínez-Baz I, Dürrwald R, Meijer A, Melo A, Oroszi B, Hagey TS, Kurečić Filipović S, Dijkstra F, Gomez V, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Merdrignac L, et al. Among authors: bacci s. Influenza Other Respir Viruses. 2024 Nov;18(11):e70009. doi: 10.1111/irv.70009. Influenza Other Respir Viruses. 2024. PMID: 39523781 Free PMC article.
Effectiveness of the autumn 2023 COVID-19 vaccine dose in hospital-based healthcare workers: results of the VEBIS healthcare worker vaccine effectiveness cohort study, seven European countries, season 2023/24.
Savulescu C, Prats-Uribe A, Brolin K, Uusküla A, Bergin C, Fleming C, Murri R, Zvirbulis V, Zavadska D, Gaio V, Popescu CP, Hrisca R, Cisneros M, Latorre-Millán M, Lohur L, McGrath J, Ferguson L, De Gaetano Donati K, Abolina I, Gravele D, Machado A, Florescu SA, Lazar M, Subirats P, Clusa Cuesta L, Sui J, Kenny C, Santangelo R, Krievins D, Barzdina EA, Valadas Henriques C, Kosa AG, Pohrib SM, Muñoz-Almagro C, Milagro A, Bacci S, Nardone A; VEBIS HCW VE study group; Collaborators in VEBIS HCW study group. Savulescu C, et al. Among authors: bacci s. Euro Surveill. 2024 Oct;29(44):2400680. doi: 10.2807/1560-7917.ES.2024.29.44.2400680. Euro Surveill. 2024. PMID: 39484687 Free PMC article.
Corrigendum to "Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: results from the VEBIS primary care test-negative design study, September 2023-January 2024" [Vaccine 42(19) (2024)].
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Paula Rodrigues A, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: bacci s. Vaccine. 2024 Oct 3;42(23):126089. doi: 10.1016/j.vaccine.2024.06.056. Epub 2024 Jul 8. Vaccine. 2024. PMID: 38971666 Free PMC article. No abstract available.
COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans.
Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, Meijer A, Rodrigues AP, Sève N, Ilic M, Latorre-Margalef N, Lazar M, Maurel M, Melo A, Andreu Ivorra B, Casado I, Horváth JK, Buda S, Bennett C, de Lange M, Guiomar R, Enouf V, Mlinaric I, Samuelsson Hagey T, Dinu S, Rumayor M, Castilla J, Oroszi B, Dürrwald R, O'Donnell J, Hooiveld M, Gomez V, Falchi A, Kurecic Filipovic S, Dillner L, Popescu R, Bacci S, Kaczmarek M, Kissling E; VEBIS Primary Care Vaccine Effectiveness Group. Laniece Delaunay C, et al. Among authors: bacci s. JAMA Netw Open. 2024 Jul 1;7(7):e2419258. doi: 10.1001/jamanetworkopen.2024.19258. JAMA Netw Open. 2024. PMID: 38949812 Free PMC article.
Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, Oroszi B, Sève N, Rodrigues AP, Martínez-Baz I, Meijer A, Mlinarić I, Latorre-Margalef N, Lazăr M, Pérez-Gimeno G, Dürrwald R, Bennett C, Túri G, Rameix-Welti MA, Guiomar R, Castilla J, Hooiveld M, Kurečić Filipović S, Samuelsson Hagey T, Dijkstra F, Borges V, Ramos Marín V, Bacci S, Kaczmarek M, Kissling E; European primary care VE group. Laniece Delaunay C, et al. Among authors: bacci s. Vaccine. 2024 Jul 25;42(19):3931-3937. doi: 10.1016/j.vaccine.2024.05.067. Epub 2024 Jun 4. Vaccine. 2024. PMID: 38839521 Free PMC article.
199 results